Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Krista Edelman

Gastroenterology Richmond, VA Medical Doctor

NPI 1417249434 CMS profile 1310021

1630 Wilkes Ridge Pkwy Ste 202, Richmond, VA 23233

Open in the dashboard

General payments

$7,186

373 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Krista Edelman of Richmond, VA is reported in the CMS Open Payments database as having received $7,186 across 373 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,036 42
2024 General $1,091 53
2023 General $1,629 80
2022 General $1,549 78
2021 General $1,080 68
2020 General $259 15
2019 General $541 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Krista Edelman
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Krista Edelman were reported at $1,036. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Krista Edelman Gastroenterology median Middle half National median
2019 $541 $417 $126–$1,100 $163
2020 $259 $224 $74–$624 $114
2021 $1,080 $352 $106–$1,054 $132
2022 $1,549 $448 $129–$1,270 $149
2023 $1,629 $533 $150–$1,390 $160
2024 $1,091 $605 $160–$1,606 $164
2025 $1,036 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,379 177 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $708 45 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $682 41 payments
  4. Janssen Biotech, Inc. $457 19 payments
  5. Genzyme Corporation $271 10 payments
  6. Pfizer Inc. $235 14 payments
  7. QOL Medical, LLC $200 9 payments
  8. Merck Sharp & Dohme Corporation $179 8 payments
  9. Ardelyx, Inc. $164 6 payments
  10. Celgene Corporation $127 8 payments
  11. Other $784 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,034 370 payments
  2. Education $152 3 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,465 64 payments
  2. SKYRIZI Immunology $748 42 payments
  3. LINZESS $693 43 payments
  4. CREON $685 38 payments
  5. HUMIRA $548 30 payments
  6. XIFAXAN $489 26 payments
  7. SKYRIZI Immunology $457 20 payments
  8. STELARA $437 18 payments
  9. ENTYVIO $432 25 payments
  10. DUPIXENT $271 10 payments
  11. Other $2,621 143 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,236

Median for Gastroenterology: 569

Drug cost

$322,628

Median for Gastroenterology: $104,976

Branded share of claims

33.8%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entyvio Pen Vedolizumab Brand 11 $91,682
Xifaxan Rifaximin Brand 36 $75,095
Creon Lipase/Protease/Amylase Brand 14 $43,429
Linzess Linaclotide Brand 24 $31,047
Mesalamine Generic 26 $22,437
Motegrity Prucalopride Succinate Brand 16 $14,828
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 55 $9,250
Dexlansoprazole Dr Dexlansoprazole Brand 23 $9,185
Colestipol Hcl Generic 54 $4,310
Omeprazole Generic 286 $3,718

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$104,217

Medicare's payments for the services billed

Medicare patients

477

Average age 74

Services billed

937

381 women, 96 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 53%
Ischemic heart disease 26%
Osteoporosis 26%
Diabetes 24%
Depression 23%
Chronic kidney disease 20%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CREON
  • AbbVie, Inc. $154
$154 14 —
SKYRIZI
  • AbbVie, Inc. $118
$118 — —
RINVOQ
  • AbbVie, Inc. $117
$117 — —
VELSIPITY
  • PFIZER INC. $110
$110 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $74
$74 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

373 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record